Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.
- SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No.
- The patent is the first issued for CD388, and includes claims directed to the composition of matter of CD388.
- The patent is projected to expire in 2039 plus any available patent term extension.
- We are pleased to receive the first U.S. patent for our lead flu DFC, CD388, as we establish robust IP protection for this new class of drug, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.